SITC 2017 Abstract Titles – Combination Therapy

#

Title

Authors

Affiliations

Keywords

P255

Depleting blood arginine with AEB1102 (Pegzilarginase) exerts additive anti-tumor and synergistic survival benefits when combined with immunomodulators of the PD-1 pathway

Giulia Agnello¹, Mark Badeaux¹, Susan Alters¹, David Lowe¹, Scott Rowlinson¹

¹Aeglea BioTherapeutics, Inc., Austin, TX, USA

Tumor microenvironment | Checkpoint blockade | Metabolism

P256

G100 and ZVex®-based combination immunotherapy induces near complete regression of established glioma tumors in mice

Tina C. Albershardt¹, Jordan E. Krull¹, Reice D. James¹, Peter Berglund¹, Jan ter Meulen¹

¹Immune Design, Seattle, WA, USA

Tumor microenvironment | Tumor antigens | Vaccine | Targeted therapy | Antigen presenting cells

P257

Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients

Helen Angell¹, Vidalba Rocher Ros¹, Nathan Standifer², Zhongwu Lai¹, Christopher Gresty¹, Jean-Pierre Delord³, Maja De Jonge⁴, Sophie Postel-Vinay⁵, Antoine Italiano⁶, Matthew G Krebs⁷, Bella Kaufman⁸, Yeon Hee Park⁹, Susan Domchek¹⁰, Pia Herbolsheimer¹¹, Darren Hodgson¹

¹AstraZeneca, Cambridge, United Kingdom ²MedImmune, Mountain View, CA, USA ³Institut Claudius Regaud-Oncopole, Toulouse, France ⁴Erasmus MC Cancer Institute, Rotterdam, Netherlands ⁵Gustave Roussy Cancer Campus, Villejuif, France ⁶Institut Bergonié, Bordeaux, France ⁷The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom ⁸Sheba Medical Centre, Ramat Gan, Israel ⁹Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea ¹⁰Hospital of the University of Pennsylvania, Philadelphia, PA, USA ¹¹AstraZeneca, Gaithersburg, MD, USA

Biomarkers | Clinical trial | Gene expression | Targeted therapy

P258

Resource Use and Cost Implications Associated with Treatment-free Interval Experienced on Immunotherapies

Michael Atkins¹, Ahmad Tarhini², Apoorva Ambavane³, David McDermott⁴, Komal Gupte-Singh⁵, Josh Weng³, Corey Ritchings⁵, Meredith Regan⁷, Agnes Benedict⁶, Sumati Rao⁵

¹Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA ²University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA, USA ³Evidera, Inc., Bethesda, MD, USA ⁴Beth Israel Deaconess Medical Center, Boston, MA, USA ⁵Bristol-Myers Squibb, Princeton, NJ, USA ⁶Evidera, Inc., Budapest, Hungary ⁷Dana-Farber Cancer Institute, Boston, MA, USA

Checkpoint blockade | Solid tumors

P259

Pushing the accelerator and releasing the brake: testing the soluble LAG-3 protein (IMP321), an antigen presenting cell activator, together with pembrolizumab in unresectable or metastatic melanoma.

Victoria Atkinson¹, Andrew Haydon², Melissa Eastgate³, Amitesh Roy⁴, Adnan Khattak⁵, Christian Mueller⁶, Tina Dunkelmann⁶, Chrystelle Brignone⁷, Frederic Triebel⁷

¹Princess Alexandra Hospital, 4102 Woolloongabba, Australia ²Alfred Hopital, 3004 Melbourne, Australia ³Royal Brisbane and Women's Hospital, 429 Herston, Australia ⁴Flinders Medical Centre, Bedfork Park, Australia ⁵Fiona Stanley Hospital, Murdoch, Australia ⁶Prima BioMed GmbH, Berlin, Germany ⁷Immutep S.A.S., Châtenay-Malabry, France

Antigen presenting cells | Adoptive immunotherapy | Clinical study | Checkpoint blockade | Clinical trial | Immune adjuvant | Solid tumors | Immune monitoring | Costimulation

P260

Glembatumumab Vedotin (GV), an Anti-gpNMB Antibody-Drug Conjugate (ADC), in Combination with Varlilumab (V), an Anti-CD27 Antibody, in Advanced Melanoma

Omid Hamid¹, Anna C. Pavlick², C. Lance Cowey³, Lowell Hart⁴, Douglas B. Johnson⁵, Jose Lutzky⁶, Aaron Alizadeh⁷, David Spigel⁸, Neal Rothschild⁹, April Salama¹⁰, Robert Weber¹¹, Jason J. Luke¹², Ying Wang¹³, Michael Yellin¹³, Yi He¹³, Rebecca G. Bagley¹³, Patrick Ott¹⁴

¹The Angeles Clinic and Research Institute, Los Angeles, CA, USA ²New York University School of Medicine, New York, NY, USA ³Baylor University Medical Center, Dallas, TX, USA ⁴Florida Cancer Specialists, Fort Myers, FL, USA ⁵Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA ⁶Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA ⁷Northside Hospital, Atlanta, GA, USA ⁸Tennessee Oncology, PLLC, Nashville, TN, USA ⁹Florida Cancer Specialists, West Palm Beach, FL, USA ¹⁰Duke University, Durham, NC, USA ¹¹St. Mary's Medical Center, San Francisco, CA, USA ¹²University of Chicago, Chicago, IL, USA ¹³Celldex Therapeutics, Inc., Hampton, NJ, USA ¹⁴Dana-Farber Cancer Institute, Boston, MA, USA

Antibody | Checkpoint blockade | Clinical study | Clinical trial | Costimulation | Solid tumors | T cell | Targeted therapy | Tumor infiltrating lymphocytes (TILs) | Tumor antigens

P261

Molecular signatures of combination immunotherapy of prostate cancer using a Listeria-based PSA vaccine and radiation

Emily Bongiorno¹, Trevor Baybutt¹, Carla Portocarrero¹, Adam Snook¹, Adam Dicker¹, Sandra Hayes², Ulrich Rodeck¹

¹Thomas Jefferson University, Philadelphia, PA, USA ²Advaxis Immunotherapeutics, Inc., Princeton, NJ, USA

Tumor microenvironment | Checkpoint blockade | Biomarkers | Tumor infiltrating lymphocytes (TILs) | Tumor evasion | Vaccine | Radiotherapy

P262

Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma

Sadna Budhu¹, Rachel Giese¹, Olivier De Henau¹, Roberta Zappasodi¹, Luis Felipe Campesato¹, Aditi Gupta¹, Christopher Barker¹, Bruce Freimark², Jedd D. Wolchok¹, Taha Merghoub¹

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA ²Peregrine Pharmaceuticals, Inc., Tustin, CA, USA

Checkpoint blockade | Radiotherapy | Tumor infiltrating lymphocytes (TILs) | Solid tumors

P263

Preclinical development of a Vaccine-Based Immunotherapy Regimen (VBIR) that breaks immunological tolerance and induces high titer and long lived T-cell responses to a tumor-associated self-antigen

Helen Cho¹, Risini Weeratna², Joe Binder¹, Bassel Akache², Rajeev Nepal³, Paul Cockle⁴, Marianne Martinic¹, Michael Dermyer¹, Stanley Dai¹, James Merson¹, Karin Jooss⁴

¹Pfizer Inc., San Diego, CA, USA ²National Research Council of Canada, Ottawa, ON, Canada ³Pfizer Canada Inc., Kirkland, QC, Canada ⁴Gritstone Oncology Inc., Emeryville, CA, USA

Immune tolerance | Tumor antigens | T cell | Vaccine | Immune monitoring | Checkpoint blockade

P264

Immune modulation by low dose sunitinib combined with a cancer vaccine based immunotherapeutic regimen provides therapeutic benefit to tumor bearing mice

Helen Cho¹, Cindy Li¹, Antonio Boccia¹, Steve Burgess¹, Terri Harder¹, Paul Cockle², Jim Eyles¹, Marianne Martinic¹, Bryan Clay¹, Kam Chan¹, Stanley Dai¹, Michael Dermyer¹, Joe Binder¹, Steve Kurzyniec³, Terrina Bayone¹, Joan Guo⁴, Robert Hollingsworth¹, James Merson¹, Karin Jooss²

¹Pfizer Inc., San Diego, CA, USA ²Gritstone Oncology Inc., Emeryville, CA, USA ³Shimadzu Scientific Instruments, San Diego, CA, USA ⁴Moderna Therapeutics, Cambridge, MA, USA

Vaccine | T cell | Immune suppression | Tumor antigens | MDSC | Immune monitoring | Checkpoint blockade | Immune tolerance | Myeloid cells | Tumor microenvironment

P265

Optimizing targeted therapy and immune checkpoint blockade therapy in Kras mutant lung cancer

Hyejin Choi¹, Jiehui Deng², Tarik Silk¹, Ann Powers¹, Jonathan Boiarsky¹, Taha Merghoub³, Kwok-Kin Wong², Jedd Wolchok¹

¹MSKCC, New York, NY, USA ²New York University Langone Medical Center, New York, NY, USA ³Medicine, New York, NY, USA

Checkpoint blockade | Targeted therapy | T cell

P266

Significant Enhancement of Expanded Natural Killer Cells against GD2 Pediatric Solid Tumors (ST) in Combination withALT-803 (IL-15 Superagonist) and Dinutuximab

Yaya Chu¹, Nang Kham Su¹, Jeremy Rosenblum¹, Hing C. Wong², Dean A. Lee³, Mitchell S Cairo¹

¹New York Medical College, Valhalla, NY, USA ²Altor Bioscience, Miramar, FL, USA ³Nationwide Children’s Hospital, Columbus, OH, USA

Adoptive immunotherapy | Pediatric tumors | NK/NK T cell | Cytokine | Targeted therapy

P267

Withdrawn

P268

Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy.

Elizabeth Evans¹, Holm Bussler¹, Crystal Mallow¹, Christine Reilly¹, Sebold Torno¹, Maria Scrivens¹, Cathie Foster¹, Alan Howell¹, Leslie Balch¹, John E. Leonard¹, Terrence L. Fisher¹, David Jenkins², Clint Allen³, Paul Clavijo³, Siwen Hu-Lieskovan⁴, Antoni Ribas⁵, Ernest Smith¹, Maurice Zauderer¹

¹Vaccinex, Rochester, NY, USA ²Tesaro, Waltham, MA, USA ³NIH/NIDCD, Bethesda, MD, USA ⁴UCLA, Los Angeles, CA, USA ⁵Vaccinex, Los Angeles, CA, USA

Antigen presenting cells | Immune contexture | Myeloid cells | Regulatory T cell (Treg) | Tumor microenvironment | Checkpoint blockade | MDSC | Tumor infiltrating lymphocytes (TILs) | Biomarkers | Clinical trial

P269

Epigenetic reprogramming of the tumor microenvironment increases tumor sensitivity to multivalent immunotherapy combinations with an IL-15 superagonist plus vaccine or immune checkpoint blockade

Kristin C. Hicks¹, Karin M. Knudson¹, Anthony S. Malamas¹, Frank R. Jones², Peter Ordentlich³, Shahrooz Rabizadeh⁴, Hing C. Wong⁵, James W. Hodge¹, Jeffrey Schlom¹, Sofia R. Gameiro¹

¹National Cancer Institute, National Institutes of Health, Bethesda, MD, USA ²Etubics Corporation, Seattle, WA, USA ³Syndax Pharmaceuticals, Inc., Waltham, MA, USA ⁴NantCell, LLC, Culver City, CA, USA ⁵Altor BioScience Corporation, Miramar, FL, USA

Vaccine | Antibody | Checkpoint blockade | Tumor microenvironment | Solid tumors | Tumor evasion

P270

Simultaneous PD-1 blockade is detrimental to the anti-tumor effects mediated by the agonist OX40 antibody

Seema Gupta¹, Rajeev Shrimali², Shamim Ahmad³, Vivek Verma¹, Peng Zeng¹, Sudha Ananth¹, Pankaj Gaur¹, Rachel Gittelman⁴, Erik Yusko⁴, Catherine Sanders⁴, Harlan Robins⁴, Scott Hammond⁵, John Janik¹, Mikayel Mkrtichyan³, Samir Khleif¹

¹Georgia Cancer Center, Augusta University, Augusta, GA, USA ²Georgia Cancer Center, Augusta University, Dallas, TX, USA ³Georgia Cancer Center, Augusta University, South San Francisco, CA, USA ⁴Adaptive Biotechnologies, Seattle, WA, USA ⁵MedImmune LLC, Gaithersburg, MD, USA

Costimulation | Tumor microenvironment | Checkpoint blockade | Antibody | Tumor infiltrating lymphocytes (TILs) | Vaccine | T cell

P271

Phase 1b/2 dose-escalation study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in combination with pembrolizumab for treatment of patients with advanced solid tumors

Wael A. Harb¹, Melissa L. Johnson², Jonathan W. Goldman³, Amy Weise⁴, Justin A. Call⁵, Arkadiusz Z. Dudek⁶, Rene Gonzalez⁷, C. Lance Cowey⁸, Sybil Zildjian⁹, Kati Maharry⁹, Ashwin Gollerkeri⁹, Justin F. Gainor¹⁰

¹Horizon Oncology Research, Inc., Lafayette, IN, USA ²Sarah Cannon Research Institute, Nashville, TN, USA ³UCLA Medical Center, Santa Monica, CA, USA ⁴Karmanos Cancer Institute, Detroit, MI, USA ⁵Utah Cancer Specialists, Salt Lake City, UT, USA ⁶Regions Cancer Care Center, St. Paul, MN, USA ⁷University of Colorado Cancer Center, Aurora, CO, USA ⁸Baylor Health Care System, Dallas, TX, USA ⁹Array BioPharma Inc., Boulder, CO, USA ¹⁰Massachusetts General Hospital, Boston, MA, USA

Tumor microenvironment | Targeted therapy | Clinical study | Clinical trial | Checkpoint blockade | Coinhibition | Solid tumors

P272

The anti-tumor effect of radiation therapy is enhanced with the addition of TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 “do not eat” signal

Lei Cui¹, Hui Chen¹, Alison O'Connor¹, Debbie Jin¹, Jeffrey Winston¹, Robert Uger¹, Lisa Johnson¹

¹Trillium Therapeutics Inc., Mississauga, ON, Canada

Radiotherapy | Monocyte/Macrophage | Tumor microenvironment | Myeloid cells | Checkpoint blockade

P273

Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma

Hsiang-Fong Kao¹, Huai-Cheng Huang¹, Bin-Chi Liao¹, Ruey-Long Hong¹

¹National Taiwan University Hospital, Taipei, Taiwan

Clinical study | Checkpoint blockade | Targeted therapy | Solid tumors

P274

Combination of NKTR-214 and radiotherapy (RT) to reverse anergy and expand tumor-specific CD8 T Cells

Joshua Walker¹, Melissa Kasiewicz², Michael McNamara², Ian Hilgart-Martiszus², Ute Hock³, Deborah Charych³, William Redmond²

¹Oregon Health & Science University, Portland, OR, USA ²Providence Portland Medical Center, Portland, OR, USA ³Nektar Therapeutics, San Francisco, CA, USA

Radiotherapy | T cell | Tumor infiltrating lymphocytes (TILs) | Cytokine | Tumor antigens | Immune tolerance

P275

HARNESSING THE INNATE AND ADAPTIVE IMMUNE SYSTEM TO ERADICATE TREATED AND DISTANT UNTREATED SOLID TUMORS.

Saul Kivimae¹, Werner Rubas¹, Rhoneil Pena¹, Marlene Hennessy¹, Yolanda Kirksey¹, Wildaliz Nieves¹, Myong Lee¹, Clive Law¹, Kavitha Bhasi¹, Phi Quach¹, Janet Cetz¹, John L. Langowski¹, Christie Fanton¹, Jode Zandro Aquino¹, Zhongxu Ren¹, Haiying Cai¹, BoLiang Deng¹, Wen Zhang¹, Neel K. Anand¹, Jennifer Riggs-Sauthier¹, Steve Doberstein¹, Jonathan Zalevsky¹

¹Nektar Therapeutics, San Francisco, CA, USA

Antigen presenting cells | Cytokine | Dendritic cell | Myeloid cells | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor antigens | TLR | Tumor microenvironment

P276

Immunoswitch particles target activation of anti-tumor CD8+ T cells to inhibit tumor growth

Alyssa Kosmides¹, John-William Sidhom¹, Andrew Fraser¹, Catherine Bessell¹, Jonathan Schneck¹

¹Johns Hopkins School of Medicine, Baltimore, MD, USA

Costimulation | Tumor microenvironment | Checkpoint blockade | Coinhibition

P277

STING agonist treatment increases response to chemotherapy and immune checkpoint blockade therapy in a syngeneic murine model of high-grade serous ovarian cancer

Abdi Ghaffari¹, Nichole Peterson¹, Kasra Khalaj¹, Andrew Robinson², Julie-Ann Francis², Madhuri Koti¹

¹Queen's University, Kingston, ON, Canada ²Kingston Health Sciences Center, Kingston, ON, Canada

Chemotherapy | Biomarkers | Chemokine | Monocyte/Macrophage | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Dendritic cell | Antigen presenting cells | Tumor microenvironment

P278

A Rational Combination of Standard of Care and Immunotherapy Increases Survival Against Glioblastoma

Erik Ladomersky¹, Derek Wainwright¹

¹Northwestern University, Chicago, IL, USA

Checkpoint blockade | Immune suppression | Metabolism | Radiotherapy | Regulatory T cell (Treg) | T cell

P279

An oral small molecule combination therapy targeting PD-L1, VISTA and Tim-3 immune inhibitory checkpoints exhibits enhanced anti-tumor efficacy in pre-clinical models of cancer

Adam Lazorchak¹, Troy Patterson¹, Yueyun Ding¹, Pottayil G. Sasikumar², Naremaddepalli S. Sudarshan², Nagaraj M. Gowda², Raghuveer K. Ramachandra², Dodheri S. Samiulla², Mohammed Rafi², Nagesh Gowda², Sreenivas Adurthi², Jiju Mani², Rashmi Nair², Murali Ramachandra², David Tuck¹, Timothy Wyant¹

¹Curis, Inc., Lexington, MA, USA ²Aurigene Discovery Technologies Limited, Bengaluru, India

Checkpoint blockade | Tumor microenvironment | Clinical study | MDSC | Immune suppression | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor evasion

P280

Combination lymphoma immunotherapy using intratumoral virus-like particles containing CpG TLR9 agonist combined with checkpoint blockade

Caitlin Lemke-Miltner¹, Sue Blackwell¹, Arthur Krieg², George Weiner¹

¹University of Iowa, Iowa City, IA, USA ²Checkmate Pharmaceuticals, Cambridge, MA, USA

Leukemia/Lymphoma | TLR | Tumor microenvironment | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs)

P281

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances antitumor efficacy of PD-L1 blockade in syngeneic murine tumor models

yanxia li¹, David Schaer¹, Marguerita O’Mahony¹, Ivan Inigo¹, Qi Li¹, Nelusha Amaladas¹, Erik Rasmussen¹, Thompson Doman², Jason Manro², Mary Murphy¹, Macrina Francisco¹, Gerald Hall¹, Michael Kalos¹, Ruslan Novosiadly¹, Bronislaw Pytowski¹

¹Eli Lilly and Company, New York, NY, USA ²Eli Lilly and Company, Indianapolis, IN, USA

Antibody | Gene expression | T cell | Immune monitoring | Biomarkers | Angiogenesis | Antigen presenting cells | Tumor microenvironment

P282

Immunostimulatory CD40L/4-1BBL Gene Therapy Enhances aPD-1 Antibody Therapy in Experimental Models

Jessica Wenthe¹, Emma Eriksson¹, Ann-Charlotte Hellström¹, Angelica Loskog¹

¹Uppsala University, Uppsala, Sweden

Costimulation | Tumor microenvironment | Checkpoint blockade | T cell | Cytokine

P283

Differential impact of chemotherapy on tumor-associated antigen-specific immunogenicity in cynomolgus macaques

Maria Josic¹, Aaron Longworth¹, Joe Binder¹, Helen Cho¹, Erick Gamelin¹, Siradanahalli Guru¹, Eugenia Kraynov¹, Steve Burgess¹, Bryan Clay¹, Charlie Huang¹, Jannine Landry¹, Mark Lesch¹, Cindy Wei Li¹, Shangjin Li¹, Pavinder Kaur¹, Sophie Muscat-King¹, Peter Weady¹, Dan Xu¹, James Merson¹, Robert Hollingsworth¹, Marianne Martinic¹

¹Pfizer, San Diego, CA, USA

Chemotherapy | Immune tolerance | Immune monitoring | Cytokine | T cell | Vaccine | Tumor antigens

P284

T cell priming by Toca 511 and 5-FC coupled with T regulatory cell depletion by αCTLA-4 synergistically enhances anti-tumor immune memory in a mouse model of glioma

Leah Mitchell¹, Kader Yagiz¹, Anthony Munday¹, Fernando Lopez¹, Daniel Mendoza¹, Douglas Jolly¹

¹Tocagen, San Diego, CA, USA

Adoptive immunotherapy | Myeloid cells | Regulatory T cell (Treg) | Tumor microenvironment | Checkpoint blockade

P285

Antibody and T cell response profiling of pancreatic cancer patients before and after chemotherapy reveals increased recognition of antigens suitable for immunotherapy

Giorgia Mandili¹, Moitza Principe¹, Emanuela Mazza¹, Sara Bulfamante¹, Laura Follia¹, Giulio Ferrero¹, Andrea Evangelista², Daniele Giordano¹, Paola Cappello¹, Francesco Novelli¹

¹University of Turin, Torino, Italy ²Hospital Città della Salute e della Scienza di Torino, Torino, Italy

Chemotherapy | Biomarkers | Proteomics | Tumor antigens | Antibody | T cell

P286

Efficacy of interleukin 2 and interleukin 15 for in situ vaccination in a mouse melanoma model.

Alexander Rakhmilevich¹, Anna Hoefges¹, Jacob Slowinski¹, Kayla Rasmussen¹, Mackenzie Heck¹, Michael Meagher², Alan Korman³, Paul Sondel¹

¹University of Wisconsin-Madison, Madison, WI, USA ²St. Jude Children’s Research Hospital/Children’s GMP, LLC, Memphis, TN, USA ³Bristol-Myers Squibb Company, Redwood City, CA, USA

Checkpoint blockade | Cytokine | Vaccine

P287

Immunological effects of checkpoint blockade plus galectin-3 inhibition with GR-MD-02 in a first-in-human phase I clinical trial

William Redmond¹, Yoshinobu Koguchi¹, Christopher Fountain¹, Peter Traber², Brendan Curti¹

¹Providence Portland Medical Center, Portland, OR, USA ²Galectin Therapeutics, Norcross, GA, USA

Myeloid cells | Checkpoint blockade | Clinical study | Immune monitoring | Clinical trial | Immune suppression | Monocyte/Macrophage | Solid tumors | Tumor infiltrating lymphocytes (TILs)

P288

KY1044, a novel anti-ICOS antibody, elicits long term in vivo anti-tumour efficacy as monotherapy or in combination with immune checkpoint inhibitors.

Richard C.A. Sainson¹, Anil Thotakura¹, Nahida Parveen¹, Gwenoline Bohris¹, Robert Rowlands¹, Miha Kosmac¹, Jamie Campbell¹, Ian Kirby¹, Volker Germaschewski¹, Matthew McCourt¹

¹Kymab Ltd, Cambridge, United Kingdom

Immune contexture | Regulatory T cell (Treg) | Tumor microenvironment | Checkpoint blockade | Targeted therapy | Antibody | Tumor infiltrating lymphocytes (TILs)

P289

Dual cIAP1/XIAP Inhibitor ASTX660 Synergizes with Radiation Therapy and PD-1 Blockade to Enhance Anti-Tumor Immunity

Roy Xiao^1,2, Clint Allen^1,3, Linda Tran¹, So-Jin Park¹, Zhong Chen¹, Carter Van Waes¹, Nicole Schmitt^1,3

¹NIDCD, NIH, Bethesda, MD, USA

Inflammation | Tumor microenvironment | Checkpoint blockade | Targeted therapy | Cytokine | Radiotherapy | Tumor infiltrating lymphocytes (TILs) | T cell

P290

Agonist Redirected Checkpoint (ARC), TIM3-Fc-OX40L, for Cancer Immunotherapy

George Fromm¹, Suresh de Silva¹, Kellsey Johannes¹, Arpita Patel¹, Josiah Hornblower¹, Taylor Schreiber¹

¹Shattuck Labs, Inc., Research Triangle Park, NC, USA

Costimulation | Checkpoint blockade | Immune suppression | T cell | Regulatory T cell (Treg)

P291

Agonist Redirected Checkpoint (ARC), SIRPα-Fc-CD40L, for Cancer Immunotherapy

Suresh de Silva¹, George Fromm¹, Arpita Patel¹, Kellsey Johannes¹, Josiah Hornblower¹, Taylor Schreiber¹

¹Shattuck Labs, Inc., Research Triangle Park, NC, USA

Costimulation | Myeloid cells | Checkpoint blockade | Coinhibition | Monocyte/Macrophage | Tumor infiltrating lymphocytes (TILs)

P292

Pre-clinical activity of a novel immunotherapy combination of CAVATAK (Coxsackievirus A21), anti-PD1 blockade and an IDO inhibitor in melanoma

Gough Au¹, Min Yuan¹, Yvonne Wong¹, Darren Shafren¹

¹Viralytics Limited, Sydney, Australia

Checkpoint blockade | Vaccine

P293

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Lillian Sun¹, Pauline Funchain², Jung-Min Song², Michael McNamara², Brian Gastman³

¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA ²Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA ³Cleveland Clinic, Cleveland, OH, USA

Checkpoint blockade | Antigen presenting cells | Tumor antigens | Solid tumors | Tumor microenvironment | T cell

P294

Cost of adverse events associated with immunotherapy monotherapy versus targeted therapy in elderly metastatic melanoma patients

Jackson Tang¹, Zhiyi Li¹, Syed Mahmood², Sameer Ghate²

¹Asclepius Analytics, New York, NY, USA ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Targeted therapy | Immune toxicity

P295

Economic burden of adverse events associated with immunotherapy and targeted therapy for metastatic melanoma in the US elderly population

Jackson Tang¹, Zhiyi Li¹, Syed Mahmood², Sameer Ghate²

¹Asclepius Analytics, New York, NY, USA ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Immune toxicity | Targeted therapy

P296

Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to dendritic cells.

Claire Vanpouille-Box¹, Julie Diamond¹, Nils Rudqvist¹, Karsten Pilones¹, Yasmeen Sarfraz¹, Silvia Formenti², Sandra Demaria¹

¹Weill Cornell Medicine, New York, NY, USA ²Weill Cornell, New York, NY, USA

Radiotherapy | Vaccine | Dendritic cell | Biomarkers

P297

Predicting the efficacy of combination immunotherapy in animal models using tumor microenvironment immune cell profiling.

Ava Vila-Leahey¹, Genevieve Weir¹, Alecia MacKay¹, Valarmathy Kaliaperumal¹, Cynthia Tram¹, Marianne Stanford¹

¹Immunovaccine, Halifax, NS, Canada

Checkpoint blockade | Immune monitoring | Tumor infiltrating lymphocytes (TILs) | T cell | Vaccine